Follow
Peter Greasley
Peter Greasley
Early Clinical Development, AstraZeneca
Verified email at astrazeneca.com
Title
Cited by
Cited by
Year
International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2
RG Pertwee, AC Howlett, ME Abood, SPH Alexander, V Di Marzo, ...
Pharmacological reviews 62 (4), 588-631, 2010
19642010
The orphan receptor GPR55 is a novel cannabinoid receptor
E Ryberg, N Larsson, S Sjögren, S Hjorth, NO Hermansson, J Leonova, ...
British journal of pharmacology 152 (7), 1092-1101, 2007
18752007
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
KM Hallow, G Helmlinger, PJ Greasley, JJV McMurray, DW Boulton
Diabetes, Obesity and Metabolism 20 (3), 479-487, 2018
4592018
Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes
MC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand, J Bělohlávek, ...
Jama 323 (14), 1353-1368, 2020
4562020
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo
LS Whyte, E Ryberg, NA Sims, SA Ridge, K Mackie, PJ Greasley, ...
Proceedings of the national Academy of sciences 106 (38), 16511-16516, 2009
3892009
Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP‐induced receptor signaling and platelet aggregation
JJJ Van Giezen, L Nilsson, P Berntsson, BM Wissing, F Giordanetto, ...
Journal of thrombosis and haemostasis 7 (9), 1556-1565, 2009
3512009
Identification and characterisation of a novel splice variant of the human CB1 receptor
E Ryberg, HK Vu, N Larsson, T Groblewski, S Hjorth, T Elebring, ...
FEBS letters 579 (1), 259-264, 2005
2082005
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
DZI Cherney, CCJ Dekkers, SJ Barbour, D Cattran, AHA Gafor, ...
The lancet Diabetes & endocrinology 8 (7), 582-593, 2020
1922020
Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function
S Petrykiv, CD Sjöström, PJ Greasley, J Xu, F Persson, HJL Heerspink
Clinical Journal of the American Society of Nephrology 12 (5), 751-759, 2017
1642017
Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF
AM Jackson, P Dewan, IS Anand, J Bělohlávek, O Bengtsson, RA de Boer, ...
Circulation 142 (11), 1040-1054, 2020
1552020
Myc induces the nucleolin and BN51 genes: possible implications in ribosome biogenesis
PJ Greasley, C Bonnard, B Amati
Nucleic acids research 28 (2), 446-453, 2000
1492000
Mutagenesis and modelling of the α1b-adrenergic receptor highlight the role of the helix 3/helix 6 interface in receptor activation
PJ Greasley, F Fanelli, O Rossier, L Abuin, S Cotecchia
Molecular pharmacology 61 (5), 1025-1032, 2002
1402002
Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability
AJ King, M Siegel, Y He, B Nie, J Wang, S Koo-McCoy, NA Minassian, ...
Science translational medicine 10 (456), eaam6474, 2018
1102018
Mutational and Computational Analysis of the α1b-Adrenergic Receptor: INVOLVEMENT OF BASIC AND HYDROPHOBIC RESIDUES IN RECEPTOR ACTIVATION AND G PROTEIN COUPLING* 210
PJ Greasley, F Fanelli, A Scheer, L Abuin, M Nenniger-Tosato, ...
Journal of Biological Chemistry 276 (49), 46485-46494, 2001
1042001
Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the …
RA Scholtes, MHA Muskiet, MJB van Baar, AC Hesp, PJ Greasley, ...
Diabetes Care 44 (2), 440-447, 2021
922021
Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
CCJ Dekkers, CD Sjöström, PJ Greasley, V Cain, DW Boulton, ...
Diabetes, Obesity and Metabolism 21 (12), 2667-2673, 2019
912019
Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus
AS Go, J Yang, TC Tan, CS Cabrera, BV Stefansson, PJ Greasley, ...
BMC nephrology 19, 1-13, 2018
872018
Big pharma screening collections: more of the same or unique libraries? The AstraZeneca–Bayer Pharma AG case
T Kogej, N Blomberg, PJ Greasley, S Mundt, MJ Vainio, J Schamberger, ...
Drug discovery today 18 (19-20), 1014-1024, 2013
802013
Scaffold hopping, synthesis and structure–activity relationships of 5, 6-diaryl-pyrazine-2-amide derivatives: a novel series of CB1 receptor antagonists
J Boström, K Berggren, T Elebring, PJ Greasley, M Wilstermann
Bioorganic & medicinal chemistry 15 (12), 4077-4084, 2007
752007
N-Arachidonoyl-l-Serine is Neuroprotective after Traumatic Brain Injury by Reducing Apoptosis
A Cohen-Yeshurun, V Trembovler, A Alexandrovich, E Ryberg, ...
Journal of Cerebral Blood Flow & Metabolism 31 (8), 1768-1777, 2011
642011
The system can't perform the operation now. Try again later.
Articles 1–20